{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.666.5.2350",
  "meta" : {
    "versionId" : "12",
    "lastUpdated" : "2016-03-31T01:00:12.000-04:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "Lantana EH Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2022-12-15"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2016-03-31"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2350",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.666.5.2350"
    }
  ],
  "version" : "20160331",
  "name" : "ImmunocompromisedTherapiesI9",
  "title" : "Immunocompromised Therapies I9",
  "status" : "active",
  "experimental" : false,
  "date" : "2016-03-31T01:00:12-04:00",
  "publisher" : "Lantana EH Steward",
  "jurisdiction" : [
    {
      "extension" : [
        {
          "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason",
          "valueString" : "UNKNOWN"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: This set of values contains procedures for patients who have had  immunocompromising therapies.),(Data Element Scope: The intent of this data element is to identify patients who have had immunocompromising therapies. Using the Quality Data Model, this particular element will map to the Procedure  category.),(Inclusion Criteria: Include codes representing  immunocompromised therapies including systemic chemotherapy, radiation, corticosteroid and other immunosuppressive therapies using  the  ICD 9 CM  code system.),(Exclusion Criteria: None.)",
  "compose" : {
    "include" : [
      {
        "system" : "http://hl7.org/fhir/sid/icd-9-cm",
        "concept" : [
          {
            "code" : "00.10",
            "display" : "Implantation of chemotherapeutic agent"
          },
          {
            "code" : "00.15",
            "display" : "High-dose infusion interleukin-2 [IL-2]"
          },
          {
            "code" : "17.70",
            "display" : "Intravenous infusion of clofarabine"
          },
          {
            "code" : "99.25",
            "display" : "Injection or infusion of cancer chemotherapeutic substance"
          },
          {
            "code" : "99.28",
            "display" : "Injection or infusion of biological response modifier [BRM] as an antineoplastic agent"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:a156fef4-b6e0-4dd0-8211-7ad52d3ae714",
    "timestamp" : "2023-06-29T17:57:43-04:00",
    "total" : 5,
    "offset" : 0,
    "parameter" : [
      {
        "name" : "count",
        "valueInteger" : 1000
      },
      {
        "name" : "offset",
        "valueInteger" : 0
      }
    ],
    "contains" : [
      {
        "system" : "http://hl7.org/fhir/sid/icd-9-cm",
        "version" : "2013",
        "code" : "00.10",
        "display" : "Implantation of chemotherapeutic agent"
      },
      {
        "system" : "http://hl7.org/fhir/sid/icd-9-cm",
        "version" : "2013",
        "code" : "00.15",
        "display" : "High-dose infusion interleukin-2 [IL-2]"
      },
      {
        "system" : "http://hl7.org/fhir/sid/icd-9-cm",
        "version" : "2013",
        "code" : "17.70",
        "display" : "Intravenous infusion of clofarabine"
      },
      {
        "system" : "http://hl7.org/fhir/sid/icd-9-cm",
        "version" : "2013",
        "code" : "99.25",
        "display" : "Injection or infusion of cancer chemotherapeutic substance"
      },
      {
        "system" : "http://hl7.org/fhir/sid/icd-9-cm",
        "version" : "2013",
        "code" : "99.28",
        "display" : "Injection or infusion of biological response modifier [BRM] as an antineoplastic agent"
      }
    ]
  }
}
